SEC Form 4 · accession 0001209191-18-056048
PhaseBio Pharmaceuticals Inc · PHAS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Kenneth B Lee Jr.
10% Owner
Robert Alexander Ingram
10% Owner
Douglas Reed M.D.
10% Owner
Hatteras Ventures Partners III LP
10% Owner
Hatteras Venture Affiliates III Lp
10% Owner
John Crumpler
10% Owner
Hatteras Venture Advisors III, LLC
10% Owner
Venture Capital Multiplier Fund
10% Owner
Hatteras Venture Partners I, LP
10% Owner
Catalysta Ventures, LLC
10% Owner
Period of report
Oct 22, 2018
Accepted (ET)
Oct 24, 2018 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 22, 2018 | C | 52,690 | — | A | 52,690 | I | By Hatteras Venture Partners I, LP |
| Common StockF1,F3 | Oct 22, 2018 | C | 1,683,420 | — | A | 1,683,420 | I | By Hatteras Venture Partners III, LP |
| Common StockF3 | Oct 22, 2018 | P | 137,513 | $5.00 | A | 1,820,933 | I | By Hatteras Venture Partners III, LP |
| Common StockF1,F3 | Oct 22, 2018 | C | 150,612 | — | A | 150,612 | I | By Hatteras Venture Affiliates III, LP |
| Common StockF3 | Oct 22, 2018 | P | 12,487 | $5.00 | A | 163,099 | I | By Hatteras Venture Affiliates III, LP |
| Common StockF1,F2 | Oct 22, 2018 | C | 4,846 | — | A | 4,846 | I | By Catalysta Ventures, LLC |
| Common StockF1,F3 | Oct 22, 2018 | C | 266,481 | — | A | 266,481 | I | By Venture Capital Multiplier Fund |
| Common StockF3 | Oct 22, 2018 | P | 150,000 | $5.00 | A | 416,481 | I | By Venture Capital Multiplier Fund |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Purchase Series B Preferred StockF3,F5,F1 | $0.12 | Oct 22, 2018 | X | 19,061 | D | — | — | Series B Preferred Stock | 19,061 | 0 | I |
| Series B Preferred StockF3,F1 | — | Oct 22, 2018 | X | 19,061 | A | — | — | Common Stock | 19,061 | 1,045,222 | I |
| Series B Preferred StockF3,F1 | — | Oct 22, 2018 | S | 458 | D | — | — | Common Stock | 458 | 1,044,764 | I |
| Warrants to Purchase Series B Preferred StockF3,F5,F1 | $0.12 | Oct 22, 2018 | X | 1,731 | D | — | — | Series B Preferred Stock | 1,731 | 0 | I |
| Series B Preferred StockF3,F1 | — | Oct 22, 2018 | X | 1,731 | A | — | — | Common Stock | 1,731 | 94,916 | I |
| Series B Preferred StockF3,F1 | — | Oct 22, 2018 | S | 42 | D | — | — | Common Stock | 42 | 94,874 | I |
| Warrants to Purchase Series C-1 Preferred StockF3,F5,F1 | $0.12 | Oct 22, 2018 | X | 47,458 | D | — | — | Series C-1 Preferred Stock | 47,458 | 0 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | X | 47,458 | A | — | — | Common Stock | 47,458 | 150,459 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | S | 1,139 | D | — | — | Common Stock | 1,139 | 149,320 | I |
| Warrants to Purchase Series C-1 Preferred StockF3,F5,F1 | $0.12 | Oct 22, 2018 | X | 4,309 | D | — | — | Series C-1 Preferred Stock | 4,309 | 0 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | X | 4,309 | A | — | — | Common Stock | 4,309 | 13,662 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | S | 104 | D | — | — | Common Stock | 104 | 13,558 | I |
| Warrants to Purchase Series C-1 Preferred StockF3,F5,F1 | $0.12 | Oct 22, 2018 | X | 41,414 | D | — | — | Series C-1 Preferred Stock | 41,414 | 0 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | X | 41,414 | A | — | — | Common Stock | 41,414 | 41,414 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | S | 994 | D | — | — | Common Stock | 994 | 40,420 | I |
| Series 1 Preferred StockF2,F1 | — | Oct 22, 2018 | C | 52,690 | D | — | — | Common Stock | 52,690 | 0 | I |
| Series 1 Preferred StockF3,F1 | — | Oct 22, 2018 | C | 42,530 | D | — | — | Common Stock | 42,530 | 0 | I |
| Series 1 Preferred StockF3,F1 | — | Oct 22, 2018 | C | 3,862 | D | — | — | Common Stock | 3,862 | 0 | I |
| Series 1 Preferred StockF2,F1 | — | Oct 22, 2018 | C | 4,846 | D | — | — | Common Stock | 4,846 | 0 | I |
| Series AA Preferred StockF3,F1 | — | Oct 22, 2018 | C | 174,699 | D | — | — | Common Stock | 174,699 | 0 | I |
| Series AA Preferred StockF3,F1 | — | Oct 22, 2018 | C | 13,609 | D | — | — | Common Stock | 13,609 | 0 | I |
| Series B Preferred StockF3,F1 | — | Oct 22, 2018 | C | 1,044,764 | D | — | — | Common Stock | 1,044,764 | 0 | I |
| Series B Preferred StockF3,F1 | — | Oct 22, 2018 | C | 94,874 | D | — | — | Common Stock | 94,874 | 0 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | C | 149,320 | D | — | — | Common Stock | 149,320 | 0 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | C | 13,558 | D | — | — | Common Stock | 13,558 | 0 | I |
| Series C-1 Preferred StockF3,F1 | — | Oct 22, 2018 | C | 40,420 | D | — | — | Common Stock | 40,420 | 0 | I |
| Series D Preferred StockF3,F1 | — | Oct 22, 2018 | C | 272,107 | D | — | — | Common Stock | 272,107 | 0 | I |
| Series D Preferred StockF3,F1 | — | Oct 22, 2018 | C | 24,709 | D | — | — | Common Stock | 24,709 | 0 | I |
| Series D Preferred StockF3,F1 | — | Oct 22, 2018 | C | 226,061 | D | — | — | Common Stock | 226,061 | 0 | I |
Explanation of responses
- F1Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- F2Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
- F3HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
- F4Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- F5The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.